A randomized controlled trial of precision bezlotoxumab treatment for Clostridioides difficile infection
Christos Psarrakis, Nikolaos-Renatos Tziolos, Vicky Matzarakis, Vinod Kumar et autres
Early risk recognition for organ dysfunction and death by Clostridioides difficile infection (CDI) is an unmet need. A prediction score is developed in the BEYOND study (ClinicalTrials.gov; NCT02573571, NCT04725123, and NCT05304715). At the first stage, using 153 patients and 150 comparators, the …
gr, nl (code pays fourni par la source)
2 citations
Cell Reports Medicine